After signing up, you'll start to receive regular news updates from us.
Genpathway to Offer Genome-Wide DNA Methylation Assays and Analysis
Complete the form below to unlock access to ALL audio articles.
Genpathway has announced that it will begin offering genome-wide DNA methylation assays, analysis, and services to pharmaceutical, biotechnology, and academic/institutional researchers.
These assays are an expansion of Genpathway's recently announced offering of comprehensive ChIP (chromatin immunoprecipitation)-on-Chip assays, analysis, and services for scientists using the Affymetrix GeneChip® Tiling Arrays.
The Genpathway Methylated DNA IP-on-Chip™ assays is designed to detect and quantify DNA methylation patterns across the entire genome, made possible by combining Genpathway's DNA IP assays and services with the high-throughput, whole-genome analysis capabilities of Affymetrix tiling arrays.
Researchers are using the DNA methylation and ChIP-on-Chip assays and analysis to:
- discover and validate biomarkers for cancer and other diseases
- identify and validate new drug targets
- screen compounds
- detect disease stage and follow disease progression
- stratify patients for clinical trials
- create improved predictive diagnostics
- design new targeted therapies
- monitor response to treatment
"Because methylated DNA changes may be reversible, gaining an understanding of their patterns in normal vs. diseased cells may lead to new treatment paradigms," said Mary Warren, PhD, Chief Scientific Officer of Genpathway.
"Scientists have been evaluating methylation signatures in oncogenes and tumor suppressors, and there are many other diseases for which characterization of DNA methylation patterns may be useful for identifying disease and drug mechanisms, and for developing new diagnostic tests and therapeutic approaches."
"Combining Affymetrix' genome-wide tiling arrays with Genpathway's assays, analysis, and services is a very powerful combination of technologies that provides customers with an immediate, total solution for analyzing gene transcription, gene regulation by transcription factors, and epigenetic changes," said Benjamin Monderer, PhD, Chief Executive Officer of Genpathway.
"We are pleased to be teaming up with Affymetrix to provide this latest offering - the first high-throughput, whole-genome method to detect DNA methylation without sequence limitations - for scientists working in many diverse areas ranging from basic research through drug discovery and preclinical/clinical R&D."
"DNA methylation is a critical marker for cancer researchers. Genpathway's methylation assay combined with the Affymetrix GeneChip Tiling Arrays provides researchers with a complete solution to study methylation events across genomes," said Alicia Burt, Product Line Manager at Affymetrix.
"We are proud to be working closely with Genpathway to provide total solutions to both pharmaceutical and academic researchers."
Genpathway is offering three types of assays for discovery and characterization of methylated DNA regions:
- Genpathway Methylated DNA IP-on-Chip/Tiling™: Genome-wide assay using whole-genome tiling arrays
- Genpathway Methylated DNA IP-on-Chip/Promoter™: Detection of methylated DNA in promoter regions
- Genpathway Methylated DNA Query™: Gene-by-gene analysis based on quantitative polymerase chain reaction (Q-PCR)
